Open Access

Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance

  • Authors:
    • Hongyan Ji
    • Li Chen
    • Yunpeng Dai
    • Xiaojun Sun
    • Xiuli Li
    • Qi Wang
    • Daoxin Ma
    • Dongdong Du
    • Ping Zhao
    • Yulin Wang
  • View Affiliations

  • Published online on: September 18, 2017     https://doi.org/10.3892/ol.2017.6981
  • Pages: 5811-5818
  • Copyright: © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cluster of differentiation (CD)133 is considered to be a marker of leukemia stem cells (LSCs), which are one of the primary causes of occurrence, drug resistance and relapse of acute lymphoblastic leukemia (ALL). CD82, an adhesion molecule, performs an important role in the interaction between LSCs and their niche. The purpose of the present study was to assess CD133 and CD82 expression in patients with pediatric ALL, and to evaluate the association with the clinical data. Using flow cytometric assessment and reverse transcription‑polymerase chain reaction, CD133 and CD82 expression levels were measured in the bone marrow (BM) of 37 patients with newly diagnosed (ND) pediatric ALL [ALL‑ND; 30 B‑cell‑ALL (B‑ALL) and 7 T‑cell‑ALL (T‑ALL)], in 22 patients with complete remission pediatric ALL (ALL‑CR) and in 16 age‑matched children without BM disease. BM plasma CD82 concentrations were measured by ELISA. The CD82 mRNA expression level in the patients with ALL‑ND was significantly higher compared with that in the controls. CD82 mRNA expression levels in pediatric patients with B cell‑ALL (B‑ALL) were higher than those in ALL‑CR patients and controls. For T‑ALL, CD82 expression in ND patients was higher than in controls. CD133 mRNA expression levels in patients with pediatric B‑ALL‑ND were higher than that of controls and patients with ALL‑CR. The frequency of CD34+ cells in pediatric ALL was significantly higher than that in controls. Frequencies of CD34+CD133+ or CD34+CD82+ cells in pediatric ALL were higher than those in controls. A positive association was observed between CD133 and CD82 mRNA expression in patients with B‑ALL. A significant association was observed between CD133 mRNA expression and the hyperdiploid karyotype. Therefore, it was considered that CD133 and CD82 may serve an important role in the evolution of pediatric ALL. CD133 and CD82 should be considered as potential markers for the prognosis of patients with ALL.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ji H, Chen L, Dai Y, Sun X, Li X, Wang Q, Ma D, Du D, Zhao P, Wang Y, Wang Y, et al: Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance. Oncol Lett 14: 5811-5818, 2017
APA
Ji, H., Chen, L., Dai, Y., Sun, X., Li, X., Wang, Q. ... Wang, Y. (2017). Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance. Oncology Letters, 14, 5811-5818. https://doi.org/10.3892/ol.2017.6981
MLA
Ji, H., Chen, L., Dai, Y., Sun, X., Li, X., Wang, Q., Ma, D., Du, D., Zhao, P., Wang, Y."Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance". Oncology Letters 14.5 (2017): 5811-5818.
Chicago
Ji, H., Chen, L., Dai, Y., Sun, X., Li, X., Wang, Q., Ma, D., Du, D., Zhao, P., Wang, Y."Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance". Oncology Letters 14, no. 5 (2017): 5811-5818. https://doi.org/10.3892/ol.2017.6981